Ticker

Rapid Micro Biosystems (RPID) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Rapid Micro Biosystems (NASDAQ: RPID) reported fourth-quarter and full-year 2025 results highlighting record quarterly revenue, increased system placements, and expanding recurring revenue, while also outlining expectations for revenue growth and gross margin improvement in 2026. Fourth-quarter results set revenue and placement records Management said fourth-quarter revenue rose 37% year-over-year to a quarterly…

Rapid Micro Biosystems, Inc. posted strong FY25 revenue growth, driven by Growth Direct system placements, but remains unprofitable with a $47M net loss. RPID's growth hinges on large multi-system orders from major pharmaceutical manufacturers, with recurring revenue from consumables and services now 53% of total revenue. A premium valuation (6.4x P/S) reflects high expectations for platform adoption, but negative…

Rapid Micro Biosystems, Inc. (RPID) Q4 2025 Earnings Call Transcript

Reports record fourth quarter  2025 total revenue of $11.3 million , representing 37% growth compared to fourth quarter 2024 Reports full year 2025 total revenue of $33.6 million , representing 20% growth compared to 2024 Amgen expands global Growth Direct system rollout with significant multi-system order in the fourth quarter 2025; will sponsor North American Growth Direct Day in the second quarter 2026 Samsung…